Digital Solutions to Drug Adherence

Non-adherence to medications, whether due to missed doses, drugs taken at the wrong time, or not taken at all, is a huge issue in healthcare, and can mean worse outcomes for patients. This has an economic impact on healthcare systems… Read »

The Changing Landscape for Pharma and Physician Interactions

A 2019 ePharma study from Decision Resources Group (DRG) found that an increasing number of physicians are searching for drug and treatment information on their own, rather than relying on meetings with pharmaceutical sales reps.   According to the report,… Read »

The SMA Market: Assessing the Unknowns

The FDA approvals of Biogen’s Spinraza (nusinersen) and Novartis’ gene therapy for spinal muscular atrophy (SMA), Zolgensma, were landmark events that brought to market the first disease-modifying therapies for this often devastating, genetic neuromuscular disease. They also form the basis… Read »

New Risk-Based Oversight of Software as a Medical Device

Digital initiatives and artificial intelligence/machine learning are rapidly becoming central elements of health care. In particular, new tools, apps and devices are fulfilling a variety of needs related to clinical decision support (CDS) that can range from simple tools for… Read »

The Relationship Between ICER and Industry is Evolving

The relationship between pharma and the Institute for Clinical and Economic Review (ICER) has seen evolution, since ICER began ruling on the clinical and economic value of drugs, medical devices and other healthcare interventions. Of the 79 treatments that ICER… Read »

Driving CAR-T beyond oncology

CAR-T cell therapies – T cells tagged with chimeric antigen receptors – have only been on the market for a couple of years, but have already been hailed as a game changer in the treatment of some cancers, and even… Read »

FDA Policy Changes Spur Spate of New Diabetes Collaborations

Effective diabetes care is a complex, information-rich daily challenge. Besides lowering blood glucose levels, patients need to cope with the risk of hypoglycemia, manage the effects of their dietary choices and activity levels, and monitor the potential side-effects associated with… Read »

ESMO 2019: Translating Science into Better Cancer Care

The field of oncology has seen a number of significant advances in recent years. The considerable number of positive reports from the 2019 Congress of the European Society for Medical Oncology (ESMO) last month clearly reflected the meeting’s theme —… Read »

Psychedelic Drug Research Making a Comeback

In the 1950s and early 1960s, researchers within both academic and governmental institutions extensively investigated the clinical potential of psychedelic drugs, notably both LSD and psilocybin, the psychoactive substance in “magic mushrooms.” This early research aimed to understand the biological… Read »

Long Awaited CMS Rules on Medicare Coverage for CAR-T Therapies

In August, the Centers for Medicare and Medicaid Services (CMS) finalized long-sought rules framing the coverage of chimeric antigen receptor T-cell (CAR-T) treatments. Two CAR-T therapeutics are currently on the market: Gilead’s Yescarta and Novartis’ Kymriah, both approved for diffuse… Read »

1 2 3 19